Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132612 · ClinicalTrials.gov registry record · Phase 2
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT01132612 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 275 participants.
The verdict
NCT01132612, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
Interventions
- DRUG Placebo
- DRUG AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2010-05-11 |
| Est. Completion | 2016-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132612
The ClinicalTrials.gov registry entry for NCT01132612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01132612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01132612 about?
NCT01132612 is a clinical study titled "AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis". The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT01132612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2010-05-11. Estimated completion is 2016-10-18.
What interventions are being tested in trial NCT01132612?
The interventions under investigation include: Placebo (DRUG), AIN457 (DRUG).
Who is sponsoring clinical trial NCT01132612?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.